文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌组织学类型预测立体定向放疗应答

Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
PubMed 文献 · Radiother Oncol · 2017-09-14

该研究分析2004至2016年126例接受SBRT的早期腺癌或鳞癌患者,中位随访22个月,2年OS、LC和DC分别为68%、90%和79%。组织学亚型是LC的主要独立预后因素,鳞癌LC为81%,高风险和非高风险腺癌分别为96%和100%;当EQD2≥150Gy时各亚型LC差异不再显著。

要点

  • 组织学亚型是非小细胞肺癌SBRT后局部控制的独立预后因素。
  • 鳞癌局部控制低于腺癌,高风险和非高风险腺癌分别为96%和100%。
  • EQD2≥150Gy时组织学亚型间局部控制差异不再显著。

核心结论

  • 非小细胞肺癌组织学亚型可预测SBRT后的局部控制概率。
  • 需前瞻性多中心研究评估组织学预后影响及SBRT剂量调整需求。

研究设计与样本

  • 回顾性分析2004至2016年126例连续接受SBRT的早期腺癌或鳞癌患者。
  • 腺癌患者进一步分为高风险或低风险肿瘤。

主要发现

  • 中位随访22个月,2年OS、LC和DC分别为68%、90%和79%。
  • 组织学亚型是LC主要独立预后因素(p=0.033)。
  • 鳞癌LC为81%,高风险腺癌为96%,非高风险腺癌为100%(p=0.026)。
  • EQD2≥150Gy时组织学亚型间LC差异不再显著(p=0.355)。

关键数值与推荐

  • 鳞癌患者LC为81%,高风险腺癌为96%,非高风险腺癌为100%(p=0.026)。
  • EQD2≥150Gy时组织学亚型间LC无显著差异(p=0.355)。

临床怎么用

  • SBRT规划时可参考组织学亚型评估局部控制风险。
  • 对鳞癌患者可考虑EQD2≥150Gy的剂量策略,但需前瞻性研究验证。

局限性

  • 回顾性研究,样本量126例,中位随访22个月。
  • 需前瞻性多中心研究评估组织学预后影响及剂量调整需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To investigate the prognostic impact of different histological subtypes of non-small cell lung cancer (NSCLC) on outcome following stereotactic body radiotherapy (SBRT) for NSCLC patients. MATERIALS AND METHODS: We analyzed 126 consecutive patients with early-stage adenocarcinoma or squamous cell carcinoma treated with SBRT from 2004 to 2016. Adenocarcinoma patients were further sub-classified as high-risk or low-risk tumors. RESULTS: With a median follow-up time of 22months, 2-year overall survival (OS), local (LC), and distant control (DC) were 68%, 90% and 79%, respectively. For LC, histologic subtype was identified as major independent prognostic factor (p=0.033): while LC was 81% for squamous cell carcinoma patients, LC was significantly improved for high-risk and even more non-high-risk adenocarcinoma patients with 96% and 100%, respectively (p=0.026). The negative prognostic impact of the histologic subtype "squamous cell carcinoma" was not evident when patients received SBRT with higher total doses in EQD2 (2Gy equivalent dose): if patients were treated with a total dose in EQD2≥150Gy, no significant difference in LC for histologic subtypes was detected anymore (p=0.355). CONCLUSION: In the current study, histologic subtypes of NSCLC predicted local control probabilities following SBRT. Prospective, multi-center studies are needed to evaluate the prognostic impact of histology and consecutively the need for SBRT dose adaptation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hörner-Rieber J, Bernhardt D, Dern J, et al. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiother Oncol. 2017. PMID: 28919006. doi:10.1016/j.radonc.2017.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。